The doses of 10 μg should replace the doses of 5 μg in newborn hepatitis B vaccination in China: A cost-effectiveness analysis

被引:16
|
作者
Yin, Juan [1 ]
Ji, Zhenhao [1 ]
Liang, Peifeng [1 ]
Wu, Qian [1 ]
Cui, Fuqiang [2 ]
Wang, Fuzhen [2 ]
Liang, Xiaofeng [2 ]
Zhuang, Guihua [1 ]
机构
[1] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Xian 710061, Shaanxi, Peoples R China
[2] Chinese Ctr Dis Control & Prevent, Beijing 100050, Peoples R China
关键词
Hepatitis B vaccine; Dose; Newborn; Cost-effectiveness analysis; Quality-adjusted life-year; VIRUS INFECTION; NATURAL-HISTORY; MATHEMATICAL-MODEL; HEPATOCELLULAR-CARCINOMA; ECONOMIC BURDEN; CHILDREN; IMMUNIZATION; ADOLESCENTS; STRATEGIES; PROTECTION;
D O I
10.1016/j.vaccine.2015.05.082
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To identify whether Chinese current series of three 5 mu g doses for newborn hepatitis B vaccination should be replaced by the series of three 10 mu g doses. Methods: A cost-effectiveness analysis was conducted from the societal perspective based on the constructed decision tree-Markov model. Model parameters were estimated from published literatures, government documents and our surveys. The expected cost and effectiveness were compared between the 3-dose 5 mu g series (the 5 mu g strategy) and the 3-dose 10 mu g series (the 10 mu g strategy), and the incremental cost-effectiveness ratio (ICER, additional cost per quality-adjusted life-years gained) was calculated. Threshold values of the efficacy difference of the two series for the ICER=0, 1 and 3 times per capita gross domestic product were analyzed under different scenarios to understand whether the 10 mu g strategy should replace the 5 mu g strategy according to the recommendation of World Health Organization. Results: The 10 mu g strategy would be cost-saving compared with the 5 mu g strategy under the base-case scenario. Under keeping all the other parameters at the base-case values or further adjusting any one of them to the value most unfavorable to the 10 mu g strategy, as long as the efficacy of 3-dose 10 mu g series was slightly higher than that of 3-dose 5 mu g series, the 10 mu g strategy would be cost-effective, highly cost-effective, or even cost-saving. Even under the most pessimistic scenario, i.e. all the other parameters, but the discount rate, at the values most unfavorable to the 10 p.g strategy, the 10 p..g strategy would be cost-effective if the efficacy difference reached higher than 1.23 percentage point. Conclusion: For newborn hepatitis B vaccination in China, the 10 mu g strategy should be cost-effective, even more possibly highly cost-effective or cost-saving compared with the current 5 mu g strategy. The doses of 10 mu g should be considered to replace the doses of 5 mu g in newborn hepatitis B vaccination in China. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3731 / 3738
页数:8
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China
    Ke, Weixia
    Zhang, Chi
    Liu, Li
    Gao, Yanhui
    Yao, Zhenjiang
    Ye, Xiaohua
    Zhou, Shudong
    Yang, Yi
    HEPATOLOGY INTERNATIONAL, 2016, 10 (06) : 924 - 936
  • [22] Cost-Effectiveness Analysis of Hepatitis E Vaccination Strategies for Swine Workers
    Wang, Fengge
    Zhou, Lu
    Lu, Yihan
    TRANSBOUNDARY AND EMERGING DISEASES, 2025, 2025 (01)
  • [23] Evaluating the cost-effectiveness of hepatitis B vaccination strategies in high-impact settings for adults
    Hall, Eric W.
    Gounder, Prabhu
    Angles, John
    Nelson, Noele P.
    Rosenberg, Eli S.
    Weng, Mark K.
    JOURNAL OF VIRAL HEPATITIS, 2022, 29 (12) : 1115 - 1126
  • [24] Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China
    Wu, Bin
    Shen, Jinfang
    Cheng, Huafeng
    BMC HEALTH SERVICES RESEARCH, 2012, 12
  • [25] Tenofovir prophylaxis for preventing mother-to-child hepatitis B virus transmission in China: A cost-effectiveness analysis
    Yin, Juan
    Liang, Peifeng
    Chen, Gang
    Wang, Fuzhen
    Cui, Fuqiang
    Liang, Xiaofeng
    Zhuang, Guihua
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 95 : 118 - 124
  • [26] COST-EFFECTIVENESS ANALYSIS OF PRENATAL SCREENING AND VACCINATION AGAINST HEPATITIS-B VIRUS - THE CASE OF BELGIUM
    TORMANS, G
    VANDAMME, P
    CARRIN, G
    CLARA, R
    EYLENBOSCH, W
    SOCIAL SCIENCE & MEDICINE, 1993, 37 (02) : 173 - 181
  • [27] Cost-effectiveness analysis of vaccination against COVID-19 in China
    Zhou, Huixuan
    Ding, Ningxin
    Han, Xueyan
    Zhang, Hanyue
    Liu, Zeting
    Jia, Xiao
    Yu, Jingjing
    Zhang, Wei
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [28] Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis
    Wu, Joseph T.
    Jit, Mark
    Zheng, Yaming
    Leung, Kathy
    Xing, Weijia
    Yang, Juan
    Liao, Qiaohong
    Cowling, Benjamin J.
    Yang, Bingyi
    Lau, Eric H. Y.
    Takahashi, Saki
    Farrar, Jeremy J.
    Grenfell, Bryan T.
    Leung, Gabriel M.
    Yu, Hongjie
    PLOS MEDICINE, 2016, 13 (03)
  • [29] The Effectiveness and Cost-Effectiveness of Screening for and Vaccination Against Hepatitis B Virus among Migrants in the EU/EEA: A Systematic Review
    Myran, Daniel T.
    Morton, Rachael
    Biggs, Beverly-Ann
    Veldhuijzen, Irene
    Castelli, Francesco
    Anh Tran
    Staub, Lukas P.
    Agbata, Eric
    Rahman, Prinon
    Pareek, Manish
    Noori, Teymur
    Pottie, Kevin
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2018, 15 (09)
  • [30] Should we treat acute hepatitis C? A decision and cost-effectiveness analysis
    Bethea, Emily D.
    Chen, Qiushi
    Hur, Chin
    Chung, Raymond T.
    Chhatwal, Jagpreet
    HEPATOLOGY, 2018, 67 (03) : 837 - 846